Avosentan reduces albumin excretion in diabetics with macroalbuminuria

Journal of the American Society of Nephrology

Volumn 20, Issue 3, 2009, Pages 655-664

  Wenzel, René R ^a   Littke, Thomas ^b   Kuranoff, Susan ^b   Jürgens, Christiane ^c   Bruck, Heike ^c   Ritz, Eberhard ^d   Philipp, Thomas ^c   Mitchell, Anna ^c  

^a Paracelsus University Salzburg (Austria)   (Austria)

^b Speedel Pharma AG   (Switzerland)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AVOSENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ALBUMINURIA; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY EXCRETION;

EID: 62149126622     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008050482     Document Type: Article

References (39)

1. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63: 1499-1507, 2003
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
4. Adler Al, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232, 2003
5. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
8. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
9. Wenzel RR: Renal protection in hypertensive patients: Selection of antihypertensive therapy. Drugs 65[Suppl 2]: 29-39, 2005
10. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446, 2008
11. Wenzel RR: Role of angiotensin-1-receptor blockers in cardiorenal disease. Curr Drug Ther 1: 47-54, 2006
12. Wenzel RR, Czyborra P, Lüscher T, Philipp T: Endothelin in cardiovascular control: The role of endothelin antagonists. Curr Hypertens Rep 1: 79-87, 1999
13. Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46: 325-415, 1994
14. Chen S, Evans T, Deng D, Cukiernik M, Chakrabarti S: Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron 90: 86-94, 2002
15. Sorokin A, Kohan DE: Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285: F579-F589, 2003
16. Peppa-Patrikiou M, Dracopoulou M, Dacou-Voutetakis C: Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: Relation to urinary albumin, blood pressure, and other factors. Metabolism 47: 1408-1412, 1998
17. Letizia C, lannaccone A, Cerci S, Santi G, Cilli M, Coassin S, Pannarale MR, Scavo D: Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res 29: 247-251, 1997
18. Amann K, Simonaviciene A, Medwedewa T, Koch A, Orth S, Gross ML, Haas C, Kuhlmann A, Linz W, Scholkens B, Ritz E: Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 12: 2572-2584, 2001
19. Pollock DM: Endothelin antagonists in the treatment of renal failure. Curr Opin Investig Drugs 2: 513-520, 2001
20. Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Borri A, Bellini G: Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 42: 752-756, 2003
21. Jürgens C, Mann J, Yildirim I, Bruck H, Schäfers R, Philipp T, Wenzel RR: The ETA-selective antagonist SPP301 reduces proteinuria in patients with diabetic nephropathy on top of high-dose AT1 receptor blockade. Kidney Blood Press Res 26: 314(A), 2003
22. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G: Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47: 450-456, 1998
23. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F, Bauer C, Neumayer HH, Raschack M: Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87: 161-169, 2001
24. Neuhofer W, Pittrow D: Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 36[Suppl 3]: 78-88, 2006
25. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS: Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143-154, 2007
26. Dieterle W, Mann J, Kutz K: Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol 44: 59-66, 2004
27. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678, 2002
28. Schlueter W, Keilani T, Batlle DC: Metabolic effects of converting enzyme inhibitors: Focus on the reduction of cholesterol and lipoprotein (a) by fosinopril. Am J Cardiol 72: 37H-44H, 1993
29. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
30. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366: 1849-1861, 2005
31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998
32. Macdougall IC: The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14: 1836-1841, 1999
33. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49: S1-S180, 2007
34. Ala-Houhala I, Vapaatalo H, Pasternack A: Intravenously administered frusemide increases glomerular permeability. Clin Sci (Lond) 73: 365-370, 1987
35. Bakris GL, Smith A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125: 201-204, 1996
36. Bakris GL, Weir MR: Salt intake and reductions in arterial pressure and proteinuria: Is there a direct link? Am J Hypertens 9: 200S-206S, 1996
37. Vedovato M, Lepore G, Coracina A, Dodesini AR, Jori E, Tiengo A, Del Prato S, Trevisan R: Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: The role of insulin resistance. Diabetologia 47: 300-303, 2004
38. Hubbuch A: Results of multicenter determination of preliminary reference values for albumin in urine of children and adults. Wien Klin Wochenschr Suppl 189: 48-49, 1991
39. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, Tokuda K: Urinary protein as measured with a pyrogallol red-molyb-date complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32: 1551-1554, 1986